Skip to content

Author

Akash Virupakshaiah

We have 3 of 35 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Aug 2026

Clinical Characteristics and Visual Outcomes of Optic Neuritis in Pediatric Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

Children with MOGAD-associated ON often return to normal visual acuity despite significant optic atrophy and a prospective longitudinal study on pediatric MOGAD-ON is warranted to validate these findings and identify biomarkers for visual outcome prediction.

Takhmina Abdul, Arina Nisanova, Anjalee Chopra et al. · 0 citations
Open access Aug 2026

Acute Attack Treatment Escalation and Subsequent Relapse Risk in Pediatric Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease

Objectives Acute treatment for myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) includes high-dose IV methylprednisolone (IVMP), with escalation to IV immunoglobulin (IVIG) and/or plasma exchange (PLEX) based on severity or incomplete response. We evaluated whether escalation at first attack infl...

Silvia Bartolomeo, Riccardo Nistri, N. Kim et al. · 0 citations
#diffusion models Open access Sep 2026

Reduced Paramagnetic Rim Visibility Signals Lesion Aging and Tissue Degeneration in Progressive Multiple Sclerosis

Underlying tissue destruction in Definite vs Probable PRLs in people with progressive MS is assessed using quantitative MRI to assess underlying tissue destruction in PRLs in people with progressive MS.

S. Sacco, Hao-Jun Zhao, Shui-Ting Cheng et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.